In this TikToktivityTM, Therapeutics and Safety, safety and efficacy trial data will be presented of available therapeutic options for anemia in LR-MDS and how to monitor and mitigate potential adverse events through dosing considerations.
This is activity 4 of 5 in this CE curriculum, Game-Changing Therapies for Treating Anemia in Patients Living with LR-MDS.
Speakers
Mikkael A. Sekeres, MD, MS
Chief, Division of Hematology and Professor of Medicine
Sylvester Cancer Center, University of Miami
Miami, FL, USA
Mikkael Sekeres is Professor of Medicine with Tenure and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine. He earned a medical degree and a master’s degree in clinical epidemiology from the University of Pennsylvania School of Medicine. Dr Sekeres completed his postgraduate training at Harvard University, finishing an internal medicine residency at Massachusetts General Hospital and a fellowship in hematology-oncology at the Dana-Farber Cancer Institute in Boston. He is chair of the medical advisory board of the Aplastic Anemia and Myelodysplastic Syndrome (MDS) International Foundation, and formerly chaired the Oncologic Drugs Advisory Committee of the F.D.A.
Dr Sekeres’ research focuses on patients with MDS and older adults with acute myeloid leukemia, and he has been the national and international primary study investigator on dozens of phase I/II/III trials. He is the author or co-author of over 450 peer-reviewed manuscripts and 650 abstracts. He was the inaugural editor-in-chief of the ASH Clinical News magazine; he is on the editorial board of several journals; has written over 100 essays for The New York Times, The Wall Street Journal, The Washington Post, Huffington Post, Slate, and The Hill, among others; and has authored 8 books, including When Blood Breaks Down: Life Lessons from Leukemia (The MIT Press 2020) and Drugs and the FDA: Safety, Efficacy, and the Public’s Trust (The MIT Press 2022).
Accreditation and Disclosure Information
Target Audience
This educational activity is designed for US- and Canadian-based community hematologists/oncologists, physician associates, nurse practitioners, and nurses who are involved in the treatment and management of anemia in patients living with LR-MDS.
Educational Objective
After completing this CE activity, the participant should be better able to:
- Appropriately evaluate the efficacy and safety of the newest game-changing therapies to optimize clinical outcomes for patients with symptomatic anemia and LR-MDS
Agenda
- Practical aspects of LR-MDS therapeutics
- Dosage and safety management
- Emphasis on patient safety
This activity is provided by MLI
Accreditation, Support and Credit
In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
PAs
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credit. Approval is valid until May 30, 2025. PAs should only claim credit commensurate with the extent of their participation.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 0.25 contact hour and 0.25 contact hour in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Support Statement
This activity is supported by an educational grant from Bristol Myers Squibb.
Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc. is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Planner/Presenter
Mikkael A. Sekeres, MD, MS
Chief, Division of Hematology and Professor of Medicine
Sylvester Cancer Center
University of Miami Miami, FL, USA
Mikkael A. Sekeres, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Bristol Myers Squibb, Kurome
Research funding: Bristol Myers Squibb
The following relationships have ended within the last 24 months:
Consultant/Advisor: Schroedinger
Chair/Planner
Andrea R. Dean, MD
Founder, Hematology Connect
Clinical Assistant Professor
Loyola University Medical Center Lombard, IL, USA
Andrea R. Dean, MD, has no relevant financial relationships with ineligible companies to disclose for this educational activity.
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact MLI at mvu@mlieducation.org.
For Physicians, if requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
About This Activity
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by an educational grant subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
Copyright © 2024 Medical Learning Institute, Inc | All Rights Reserved
Resources
Provided within the course.